Merck Serono has entered into an agreement with Ablynx to discover and develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of  $14.5 million.     Nanobodies are a new class of therapeutic proteins that contain the structural and functional properties of naturally occurring single domain antibodies. The partners will collaborate to research and develop Nanobody-based therapeutics against two disease targets.     Under t...